Identification of Novel Long Noncoding RNAs Associated with TGF-β/Smad3-Mediated Renal Inflammation and Fibrosis by RNA Sequencing
Inflammation
Male
Mice, Knockout
0303 health sciences
Binding Sites
Base Sequence
Sequence Analysis, RNA
Molecular Sequence Data
Kidney
Fibrosis
3. Good health
Mice, Inbred C57BL
Mice
03 medical and health sciences
Gene Ontology
Glomerulonephritis
Gene Expression Regulation
Animals
Female
RNA, Long Noncoding
Smad3 Protein
Protein Binding
Signal Transduction
DOI:
10.1016/j.ajpath.2013.10.007
Publication Date:
2013-11-21T06:41:04Z
AUTHORS (6)
ABSTRACT
We have previously shown that transforming growth factor-β/Smad3-dependent miRNAs play a critical role in renal inflammation and fibrosis. However, off-target effects of miRNAs limit their therapeutic application. Recently, emerging roles of long noncoding RNAs (lncRNAs) in diseases have been recognized. In this study, we used high-throughput RNA sequencing to identify the Smad3-dependent lncRNAs related to renal inflammation and fibrosis in Smad3 knockout mouse models of unilateral ureteral obstructive nephropathy and immunologically induced anti-glomerular basement membrane glomerulonephritis. Compared with wild-type mice, 151 lncRNAs in the unilateral ureteral obstructive nephropathy kidney and 413 lncRNAs in kidneys with anti-glomerular basement membrane glomerulonephritis were significantly altered in Smad3 knockout mice. Among them, 21 common lncRNAs were up-regulated in wild-type, but down-regulated in Smad3 knockout, kidneys in both disease models in which progressive renal inflammation and fibrosis were abolished when the Smad3 gene was deleted or suppressed. Real-time PCR confirmed these findings and revealed the functional link between Smad3-dependent lncRNAs np_5318/np_17856 and progressive kidney injury. Results demonstrate that the identification and characterization of functional lncRNAs associated with kidney disease may represent a promising research direction into renal disorder and may lead to the development of new lncRNA therapies for kidney diseases.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (44)
CITATIONS (132)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....